
Assistant Professor
Primary Thematic Area
M_Neurological Surgery
Secondary Thematic Area
Research Summary
Identify underlying mechanisms of brain tumor immunosuppression and evasion, with the goal to develop novel immunotherapies for brain cancer.
I am an Associate Professor in the Department of Neurological Surgery at University of California, San Francisco (UCSF). Our lab focuses on identifying molecular mechanisms mediating immune suppression and evasion in brain tumors, with the goal of developing novel immunotherapeutics for these diseases. My recent research identified that protein phosphatase 2A negatively regulated T cell and macrophage mediated anti-tumor immunity, and further demonstrated that pharmacological inhibition of PP2A synergized with PD-1 blockade in multiple type of resistant tumors including glioblastoma. Based on those findings, a Phase I/II trial (NCT03027388) of PP2A inhibitor in recurrent glioblastoma is ongoing.
Websites
Publications
PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING-Type I Interferon Signaling in Glioblastoma
Cancer research
PP2A/STRN4 Negatively Regulates STING-Type I Interferon Signaling in Tumor Associated Macrophages (in press)
Journal of Clinical Investigation
Pantothenate kinase 2 interacts with PINK1 to regulate mitochondrial quality control via acetyl-CoA metabolism.
Nature communications
Targeting Mitochondrial Oxidative Phosphorylation in Glioblastoma Therapy.
Neuromolecular medicine
Mitochondrial Dysfunction, Macrophage, and Microglia in Brain Cancer.
Frontiers in cell and developmental biology
Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma
J Neurooncol.
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.
Journal for immunotherapy of cancer
Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).
Journal for immunotherapy of cancer
Immune oncology, immune responsiveness and the theory of everything.
Journal for immunotherapy of cancer
Cancer immune resistance: can theories converge?
Emerging topics in life sciences
LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation.
Cancer letters
G-protein-coupled receptor agonist BV8/prokineticin-2 and STAT3 protein form a feed-forward loop in both normal and malignant myeloid cells.
The Journal of biological chemistry